MYND Life Sciences (MYND.C) announced they have signed a Letter of Intent (LOI) with Eyam Vaccines and Immunotherapies which outlines an Exclusive Licensing Agreement with respect to Eyam’s proprietary technologies for applications to Central Nervous System Vaccines (CNSV).
The terms of the LOI state Eyam will grant MYND an exclusive license to manufacture and distribute its CNSV globally for 20 years with a mutual option to extend upon the expiration of the agreement, in exchange for mutually agreed-upon royalty payments and research and development commitments. The royalty payments will be agreed upon in a Definitive Agreement, which will be signed at a later date.
The terms of the LOI state Eyam will grant MYND an exclusive license to manufacture and distribute its CNSV globally for 20 years
Eyam Vaccines and Immunotherapeutics is a private, Canadian-based company focused on the research and development of vaccines that are safe, efficacious, and low dose, and are currently working on CNSV.
Central Nervous System disorders can include anything from gradual loss of cognitive function (Parkinson’s, MS, Alzheimer’s) to strokes to mental health problems, such as anxiety, depression, or psychosis.
“MYNDs business strategy involves developing a multifaceted suite of CNS disorder treatment protocols which include 1) diagnostic capacity with blood markers, 2) treatment with specific psilocybin and other psychedelic analogs, and 3) immunoprotection,” stated MYND CEO, Dr. Lyle Oberg. “This agreement with Eyam will allow MYND to access yet another cutting edge technology with the development of vaccines that have the ability to prevent neurological disorders such as Major Depressive Disorder, by stopping the neuro-inflammatory process before it starts.”
While most attention with mRNA vaccines has gone towards its ability to fight COVID-19 (for good reason), it is worth paying attention to other potential illnesses that the new vaccine technology could be used to fight. Cancer and malaria, two of humanity’s biggest scourges, have been highlighted as potential ailments which mRNA vaccines could fight. Moderna has even been exploring new vaccines aimed at HIV and Zika.
While most attention with mRNA vaccines has gone towards its ability to fight COVID-19, it is worth paying attention to other potential illnesses that the new vaccine technology could be used to fight.
The collaboration with MYND will help Eyam advance the research into their CNSV, allowing them to take advantage of new technology to use vaccines to potentially address a new range of illnesses. Because central nervous system disorders covers such a wide range of afflictions, a CNSV could have plenty of applications.
“This collaboration with MYND to advance research and development for Central Nervous System Vaccines is an excellent fit for us,” stated Eyam’s Chief Executive Officer, Ryan Thomas. “Eyam’s next-generation vaccine technologies represent an exciting future for human health care, and we look forward to advancing this partnership with MYND to accelerate the development of these technologies and quickly bring them to market.”
Following today’s news, MYND shares have not changed.